Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABEL JARELL

Allopathic & Osteopathic Physicians Dermatology

NPI
1275669996
CMS profile
941407
Location
PORTSMOUTH, NH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$101,688.07

282 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABEL JARELL

NPI 1275669996 · CMS profile ID 941407

Allopathic & Osteopathic Physicians / Dermatology

PORTSMOUTH, NH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABEL JARELL, NPI 1275669996, CMS profile ID 941407. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). ABEL JARELL, NPI 1275669996, CMS profile ID 941407. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
ABEL JARELL, NPI 1275669996, CMS profile ID 941407, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 282 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1275669996?year=2021&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

282 matching records · $101,688.07 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 282 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 282.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
LEO Pharma Inc. $22.4707/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208921 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $21.1307/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851851469 CMS
E.R. Squibb & Sons, L.L.C. $33.4407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 783511049 CMS
LEO Pharma Inc. $9.2507/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208909 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $96.2407/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815980087 CMS
Incyte Corporation $77.9007/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835559831 CMS
LEO Pharma Inc. $24.5207/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208901 CMS
LEO Pharma Inc. $19.1107/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208889 CMS
LEO Pharma Inc. $8.7907/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208871 CMS
LEO Pharma Inc. $22.0107/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208879 CMS
SANOFI-AVENTIS U.S. LLC $23.9007/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526789 CMS
LEO Pharma Inc. $23.9707/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208860 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $13.3307/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815980101 CMS
UCB, Inc. $119.4207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807362815 CMS
LEO Pharma Inc. $2.1206/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208841 CMS
LEO Pharma Inc. $21.4706/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208849 CMS
LEO Pharma Inc. $22.3906/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208831 CMS
GENZYME CORPORATION $121.6006/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526775 CMS
GENZYME CORPORATION $4,215.0006/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526777 CMS
GENZYME CORPORATION $4.5006/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526779 CMS
GENZYME CORPORATION $63.8406/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526781 CMS
GENZYME CORPORATION $4.0006/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526783 CMS
Incyte Corporation $121.4706/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835559829 CMS
UCB, Inc. $13.7406/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807363681 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $24.2906/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851851475 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $17.5906/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815980099 CMS
Janssen Scientific Affairs, LLC $21.2106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788064335 CMS
SANOFI-AVENTIS U.S. LLC $16.9506/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526805 CMS
AbbVie Inc. $3,250.0006/15/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794953399 CMS
AbbVie Inc. $109.7606/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794953395 CMS
LEO Pharma Inc. $23.3806/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208819 CMS
AbbVie Inc. $91.8606/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794953391 CMS
AbbVie Inc. $26.3306/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794953387 CMS
SANOFI-AVENTIS U.S. LLC $68.6406/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526755 CMS
AbbVie Inc. $8.0706/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794953383 CMS
LEO Pharma Inc. $4.6306/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208813 CMS
UCB, Inc. $6.8606/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807311235 CMS
Amgen Inc. $22.8206/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825106013 CMS
Lilly USA, LLC $2,800.0005/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818907897 CMS
NOVARTIS PHARMACEUTICALS CORPORATION $15.7905/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815980097 CMS
PFIZER INC. $16.1405/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833425157 CMS
Regeneron Healthcare Solutions, Inc. $5.2205/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 809589711 CMS
Incyte Corporation $122.5705/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835559773 CMS
Galderma Laboratories, L.P. $16.1905/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855281995 CMS
UCB, Inc. $18.4305/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807363917 CMS
SANOFI-AVENTIS U.S. LLC $13.8805/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843526745 CMS
AbbVie Inc. $4.2405/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 794953379 CMS
LEO Pharma Inc. $11.0905/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208795 CMS
LEO Pharma Inc. $17.3005/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842208803 CMS
Lilly USA, LLC $1,400.0005/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818905615 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $210,903.71 505
PY2020 $105,282.91 218
PY2021 $101,688.07 282
PY2022 $313,917.70 519
PY2023 $464,890.35 619
PY2024 $572,358.01 703
PY2025 $570,627.97 682

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,281,764.40 423
PY2024 Recipient $5,272.24 2
PY2024 Principal investigator $1,693,450.21 704
PY2023 Recipient $14,826.00 1
PY2023 Principal investigator $1,174,385.92 435
PY2022 Recipient $1,189.00 1
PY2022 Principal investigator $972,633.31 136
PY2021 Recipient $40,692.77 3
PY2021 Principal investigator $1,080,690.25 185
PY2020 Recipient $1,817.37 4
PY2020 Principal investigator $1,523,485.54 175
PY2019 Recipient $10,937.00 1
PY2019 Principal investigator $1,714,856.13 112

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

423 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $18,286.00 12/31/2025 Non-covered Recipient Entity
StracSkin PLLC
A PHASE 2 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 16WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF RITLECITINIB PF06651600 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1228805888
Principal investigator 1 Arcutis Biotherapeutics, Inc. $5,512.00 12/19/2025 Non-covered Recipient Entity
StracSkin PLLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163802
Principal investigator 1 Janssen Research & Development, LLC $6,615.00 12/19/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427924
Principal investigator 1 Arcutis Biotherapeutics, Inc. $1,331.20 12/16/2025 Non-covered Recipient Entity
StracSkin PLLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163800
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,150.00 12/15/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH, INC
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1190313797
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 12/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289686
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 12/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289688
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 12/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223289690
Principal investigator 1 ABBVIE INC. $1,757.40 12/04/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527512
Principal investigator 1 ABBVIE INC. $1,757.40 12/04/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202527736
Principal investigator 1 Incyte Corporation $3,184.80 12/04/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597278
Principal investigator 1 Incyte Corporation $5,661.90 12/04/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597280
Principal investigator 1 CSL Behring $500.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670244
Principal investigator 1 CSL Behring $2,000.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670246
Principal investigator 1 CSL Behring $2,200.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670248
Principal investigator 1 CSL Behring $3,000.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670250
Principal investigator 1 CSL Behring $10,000.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670252
Principal investigator 1 CSL Behring $2,000.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670254
Principal investigator 1 CSL Behring $2,000.00 12/03/2025 Non-covered Recipient Entity
ALLCUTIS Research LLC
A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects No dispute reported 06/30/2026 1252670256
Principal investigator 1 Incyte Corporation $40.29 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501203
Principal investigator 1 Incyte Corporation $11.85 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501207
Principal investigator 1 Incyte Corporation $2.37 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501216
Principal investigator 1 Incyte Corporation $1.02 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501244
Principal investigator 1 Incyte Corporation $47.40 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501248
Principal investigator 1 Incyte Corporation $52.14 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501252
Principal investigator 1 Incyte Corporation $16.59 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501256
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501260
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501264
Principal investigator 1 Incyte Corporation $4.74 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501268
Principal investigator 1 Incyte Corporation $28.44 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501276
Principal investigator 1 Incyte Corporation $66.36 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501280
Principal investigator 1 Incyte Corporation $23.70 12/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501284
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,614.60 12/01/2025 Non-covered Recipient Entity
STRACSKIN PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223289051
Principal investigator 1 Incyte Corporation $5,499.00 11/25/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597270
Principal investigator 1 Incyte Corporation $570.00 11/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501104
Principal investigator 1 Incyte Corporation $900.00 11/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501108
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 11/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 11/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288539
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 11/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288541
Principal investigator 1 Incyte Corporation $2,877.30 11/14/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597266
Principal investigator 1 Janssen Research & Development, LLC $20,370.00 11/13/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427930
Principal investigator 1 Incyte Corporation $1,532.70 11/07/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597273
Principal investigator 1 ABBVIE INC. $17,144.20 11/05/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522801
Principal investigator 1 ABBVIE INC. $16,800.00 11/05/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202522803
Principal investigator 1 ABBVIE INC. $7,060.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202522871
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288031
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288033
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288035
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288037
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288039
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288041
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288043
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288045
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288047
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288049
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288051
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 11/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223288053
Principal investigator 1 ABBVIE INC. $3,000.00 10/30/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202519731
Principal investigator 1 Incyte Corporation $3,400.20 10/29/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597258
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,300.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287753
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $140.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287755
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $280.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287757
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287763
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287771
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $120.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287773
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287775
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287777
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.00 10/29/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223287779
Principal investigator 1 Incyte Corporation $4,410.00 10/23/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597262
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,611.25 10/22/2025 Non-covered Recipient Entity
STRACSKIN PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287281
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,875.00 10/17/2025 Non-covered Recipient Entity
STRACSKIN PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287083
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/17/2025 Non-covered Recipient Entity
STRACSKIN PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287101
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,000.00 10/17/2025 Non-covered Recipient Entity
STRACSKIN PLLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223287103
Principal investigator 1 Eli Lilly and Company $5,425.65 10/16/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
AN OPEN-LABEL, 24-WEEK STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AND SKIN OF COLOR No dispute reported 06/30/2026 1187871529
Principal investigator 1 ABBVIE INC. $4,600.00 10/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202514547
Principal investigator 1 Incyte Corporation $2,055.60 10/09/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597251
Principal investigator 1 Incyte Corporation $3,365.00 10/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240501100
Principal investigator 1 Incyte Corporation $1,798.00 10/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501112
Principal investigator 1 Incyte Corporation $2,768.00 10/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501116
Principal investigator 1 Incyte Corporation $2,768.00 10/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501119
Principal investigator 1 Incyte Corporation $2,768.00 10/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501123
Principal investigator 1 Incyte Corporation $32.36 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501197
Principal investigator 1 Incyte Corporation $135.40 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501200
Principal investigator 1 Incyte Corporation $59.13 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501211
Principal investigator 1 Incyte Corporation $68.70 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501220
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501224
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501228
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501232
Principal investigator 1 Incyte Corporation $24.66 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501236
Principal investigator 1 Incyte Corporation $74.04 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501240
Principal investigator 1 Incyte Corporation $8.48 10/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501272
Principal investigator 1 Janssen Research & Development, LLC $5,153.00 09/29/2025 Non-covered Recipient Entity
STRACSKIN PLLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175427936
Principal investigator 1 Arcutis Biotherapeutics, Inc. $2,033.20 09/26/2025 Non-covered Recipient Entity
StracSkin PLLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163798
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,326.71 09/26/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285961
Principal investigator 1 Incyte Corporation $1,738.80 09/23/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597237
Principal investigator 1 Incyte Corporation $2,800.00 09/23/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597241
Principal investigator 1 Incyte Corporation $15,250.00 09/23/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597244
Principal investigator 1 Incyte Corporation $1,500.00 09/23/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597248
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,206.81 09/17/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223285624
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $103.60 09/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285137
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 09/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285139
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 09/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285141
Principal investigator 1 Incyte Corporation $1,568.70 09/04/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597234
Principal investigator 1 Incyte Corporation $57.00 09/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501051
Principal investigator 1 SANOFI US SERVICES INC. $5,302.65 09/03/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116603
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,090.75 09/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223285061
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,300.00 09/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284743
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,200.00 09/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284745
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223284747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 08/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284647
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.00 08/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284649
Principal investigator 1 Incyte Corporation $4,535.10 08/26/2025 Non-covered Recipient Entity
STRACSKIN
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240597230
Principal investigator 1 Incyte Corporation $1,842.00 08/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500887
Principal investigator 1 Incyte Corporation $1,798.00 08/20/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500900
Principal investigator 1 Incyte Corporation $2,768.00 08/20/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500908
Principal investigator 1 Incyte Corporation $390.00 08/20/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500912
Principal investigator 1 Incyte Corporation $220.00 08/20/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500933
Principal investigator 1 Incyte Corporation $370.00 08/20/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500946
Principal investigator 1 Incyte Corporation $71.00 08/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501054
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,388.86 08/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223284333
Principal investigator 1 Incyte Corporation $2,303.00 08/07/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500892
Principal investigator 1 Incyte Corporation $150.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500979
Principal investigator 1 Incyte Corporation $140.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500982
Principal investigator 1 Incyte Corporation $140.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500987
Principal investigator 1 Incyte Corporation $190.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500990
Principal investigator 1 Incyte Corporation $430.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500994
Principal investigator 1 Incyte Corporation $10.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500998
Principal investigator 1 Incyte Corporation $1,500.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501002
Principal investigator 1 Incyte Corporation $45.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501005
Principal investigator 1 Incyte Corporation $40.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501009
Principal investigator 1 Incyte Corporation $120.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501014
Principal investigator 1 Incyte Corporation $110.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501017
Principal investigator 1 Incyte Corporation $110.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501022
Principal investigator 1 Incyte Corporation $40.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501039
Principal investigator 1 Incyte Corporation $170.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501076
Principal investigator 1 Incyte Corporation $70.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501080
Principal investigator 1 Incyte Corporation $150.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501084
Principal investigator 1 Incyte Corporation $40.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501088
Principal investigator 1 Incyte Corporation $120.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501092
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283917
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.00 08/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223283919
Principal investigator 1 SANOFI US SERVICES INC. $9,839.82 08/04/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116590
Principal investigator 1 Incyte Corporation $2,000.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501026
Principal investigator 1 Incyte Corporation $1,500.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501046
Principal investigator 1 Incyte Corporation $1,131.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501059
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,328.60 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283511
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $600.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $245.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283521
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $100.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283523
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223283561
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,086.20 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283711
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,708.70 08/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223283713
Principal investigator 1 Incyte Corporation $71.00 07/28/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500904
Principal investigator 1 Incyte Corporation $900.00 07/28/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500916
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $245.00 07/23/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223283002
Principal investigator 1 Incyte Corporation $1,703.00 07/22/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500879
Principal investigator 1 Incyte Corporation $2,768.00 07/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500896
Principal investigator 1 Incyte Corporation $1,949.00 07/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501030
Principal investigator 1 Incyte Corporation $2,610.00 07/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501035
Principal investigator 1 Incyte Corporation $2,768.00 07/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501043
Principal investigator 1 Incyte Corporation $1,949.00 07/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501072
Principal investigator 1 Incyte Corporation $1,842.00 07/17/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500875
Principal investigator 1 Incyte Corporation $1,932.00 07/10/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500884
Principal investigator 1 Incyte Corporation $135.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500920
Principal investigator 1 Incyte Corporation $171.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500924
Principal investigator 1 Incyte Corporation $1,001.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500929
Principal investigator 1 Incyte Corporation $71.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500937
Principal investigator 1 Incyte Corporation $868.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500942
Principal investigator 1 Incyte Corporation $912.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500951
Principal investigator 1 Incyte Corporation $355.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500954
Principal investigator 1 Incyte Corporation $150.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500958
Principal investigator 1 Incyte Corporation $541.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500962
Principal investigator 1 Incyte Corporation $270.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500966
Principal investigator 1 Incyte Corporation $44.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500971
Principal investigator 1 Incyte Corporation $90.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500975
Principal investigator 1 Incyte Corporation $846.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501064
Principal investigator 1 Incyte Corporation $135.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501068
Principal investigator 1 Incyte Corporation $90.00 07/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501095
Principal investigator 1 ABBVIE INC. $2,416.80 07/08/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202497166
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,643.50 07/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223282194
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,044.64 07/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223282208
Principal investigator 1 Incyte Corporation $11.45 07/01/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498598
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $50.00 07/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223282016
Principal investigator 1 Janssen Research & Development, LLC $7,285.00 06/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421955
Principal investigator 1 Incyte Corporation $1,798.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500771
Principal investigator 1 Incyte Corporation $1,798.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500776
Principal investigator 1 Incyte Corporation $1,798.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500779
Principal investigator 1 Incyte Corporation $2,768.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500792
Principal investigator 1 Incyte Corporation $2,768.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500796
Principal investigator 1 Incyte Corporation $2,768.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500800
Principal investigator 1 Incyte Corporation $1,798.00 06/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500871
Principal investigator 1 Incyte Corporation $8,062.00 06/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500666
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $2,500.00 06/23/2025 Non-covered Recipient Entity
Activmed Practices And Research, Inc
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1235999383
Principal investigator 1 Incyte Corporation $100.00 06/23/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500686
Principal investigator 1 Incyte Corporation $6,281.00 06/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500671
Principal investigator 1 Janssen Research & Development, LLC $486.00 06/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421942
Principal investigator 1 Eli Lilly and Company $9,757.70 06/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1187875905
Principal investigator 1 Incyte Corporation $3,365.00 06/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500662
Principal investigator 1 Incyte Corporation $3,075.00 06/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240501288
Principal investigator 1 Incyte Corporation $2,500.00 06/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240501292
Principal investigator 1 Incyte Corporation $13,500.00 06/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240501296
Principal investigator 1 Incyte Corporation $2,000.00 06/04/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240500784
Principal investigator 1 Incyte Corporation $1,500.00 06/04/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240500788
Principal investigator 1 Incyte Corporation $1,131.00 06/04/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240500813
Principal investigator 1 Incyte Corporation $1,500.00 06/04/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240500820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $30,864.40 06/04/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223280746
Principal investigator 1 ABBVIE INC. $2,458.80 06/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202487417
Principal investigator 1 Incyte Corporation $91.60 06/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498550
Principal investigator 1 Incyte Corporation $10.30 06/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498554
Principal investigator 1 Incyte Corporation $10.30 06/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498558
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 06/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280560
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 06/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280562
Principal investigator 1 Incyte Corporation $10,258.00 05/28/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500653
Principal investigator 1 SANOFI US SERVICES INC. $4,528.92 05/27/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116548
Principal investigator 1 Janssen Research & Development, LLC $4,130.00 05/26/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421936
Principal investigator 1 Arcutis Biotherapeutics, Inc. $6,500.00 05/23/2025 Non-covered Recipient Entity
StracSkin PLLC
A Phase 2, Open Label, 4-Week, Safety Study of RoflumilastCream 0.05% Administered Once Daily in Infants Aged 3Months to Less Than 2 Years with AtopicDermatitis No dispute reported 06/30/2026 1248163796
Principal investigator 1 Incyte Corporation $3,138.00 05/22/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500658
Principal investigator 1 Incyte Corporation $1,798.00 05/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500721
Principal investigator 1 Incyte Corporation $1,798.00 05/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500859
Principal investigator 1 Incyte Corporation $1,798.00 05/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500863
Principal investigator 1 Incyte Corporation $1,798.00 05/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500866
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,091.28 05/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223280072
Principal investigator 1 Incyte Corporation $30.00 05/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500691
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $60.00 05/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279350
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 05/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279352
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 05/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223279354
Principal investigator 1 ABBVIE INC. $2,647.80 05/07/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202484101
Principal investigator 1 ABBVIE INC. $231.00 05/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202482295
Principal investigator 1 Eli Lilly and Company $1.95 05/06/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187875687
Principal investigator 1 Eli Lilly and Company $25,725.00 05/06/2025 Non-covered Recipient Entity
GRANITE STATE DERMATOLOGY
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187880039
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498519
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498523
Principal investigator 1 Incyte Corporation $16.96 05/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498527
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498578
Principal investigator 1 Incyte Corporation $32.88 05/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498582
Principal investigator 1 Incyte Corporation $1,798.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500683
Principal investigator 1 Incyte Corporation $2,610.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500713
Principal investigator 1 Incyte Corporation $285.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500725
Principal investigator 1 Incyte Corporation $1,194.27 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500734
Principal investigator 1 Incyte Corporation $142.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500738
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500743
Principal investigator 1 Incyte Corporation $1,798.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500747
Principal investigator 1 Incyte Corporation $150.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500751
Principal investigator 1 Incyte Corporation $1,123.77 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500755
Principal investigator 1 Incyte Corporation $1,194.27 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500760
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500764
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500767
Principal investigator 1 Incyte Corporation $342.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500808
Principal investigator 1 Incyte Corporation $1,637.01 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500817
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500829
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500833
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500837
Principal investigator 1 Incyte Corporation $141.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500841
Principal investigator 1 Incyte Corporation $1,798.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500845
Principal investigator 1 Incyte Corporation $1,798.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500849
Principal investigator 1 Incyte Corporation $1,798.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500854
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $448.60 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278880
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,038.60 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278882
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $345.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278884
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278886
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,725.00 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278888
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $327.20 05/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278890
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,679.16 05/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223278784
Principal investigator 1 Incyte Corporation $13,136.00 04/28/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500640
Principal investigator 1 Incyte Corporation $1,703.00 04/28/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500644
Principal investigator 1 Janssen Research & Development, LLC $7,808.00 04/28/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421962
Principal investigator 1 Eli Lilly and Company $69,351.00 04/25/2025 Non-covered Recipient Entity
GRANITE STATE DERMATOLOGY
OBSERVATION PRIORITY E SHORT - LEBRIKIZUMAB - ATOPIC DERMATITIS No dispute reported 06/30/2026 1187880037
Principal investigator 1 Incyte Corporation $141.00 04/23/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500675
Principal investigator 1 Incyte Corporation $75.00 04/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500679
Principal investigator 1 Incyte Corporation $45.00 04/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500804
Principal investigator 1 Incyte Corporation $900.00 04/16/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1240500729
Principal investigator 1 SANOFI US SERVICES INC. $9,869.89 04/14/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116508
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,190.95 04/11/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223278006
Principal investigator 1 ABBVIE INC. $700.00 04/10/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202476001
Principal investigator 1 Incyte Corporation $80.00 04/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500708
Principal investigator 1 Incyte Corporation $20.00 04/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500716
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $63.00 04/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277764
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,358.32 04/09/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223277766
Principal investigator 1 SANOFI US SERVICES INC. $13,300.00 04/07/2025 Non-covered Recipient Entity
Downtown L A Research Center Inc
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226142054
Principal investigator 1 Incyte Corporation $259.70 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498497
Principal investigator 1 Incyte Corporation $31.80 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498501
Principal investigator 1 Incyte Corporation $180.20 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498505
Principal investigator 1 Incyte Corporation $233.20 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498510
Principal investigator 1 Incyte Corporation $137.80 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498515
Principal investigator 1 Incyte Corporation $339.20 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498531
Principal investigator 1 Incyte Corporation $43.04 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498535
Principal investigator 1 Incyte Corporation $32.28 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498538
Principal investigator 1 Incyte Corporation $16.14 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498541
Principal investigator 1 Incyte Corporation $137.80 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498546
Principal investigator 1 Incyte Corporation $127.20 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498562
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498566
Principal investigator 1 Incyte Corporation $21.52 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498570
Principal investigator 1 Incyte Corporation $318.00 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498574
Principal investigator 1 Incyte Corporation $43.04 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498586
Principal investigator 1 Incyte Corporation $43.04 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498590
Principal investigator 1 Incyte Corporation $26.90 04/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498594
Principal investigator 1 Incyte Corporation $2,610.00 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500695
Principal investigator 1 Incyte Corporation $1,926.00 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500699
Principal investigator 1 Incyte Corporation $1,926.00 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500704
Principal investigator 1 Incyte Corporation $2,610.00 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500824
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501136
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501139
Principal investigator 1 Incyte Corporation $68.70 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501142
Principal investigator 1 Incyte Corporation $64.72 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501147
Principal investigator 1 Incyte Corporation $91.60 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501151
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501155
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501158
Principal investigator 1 Incyte Corporation $76.22 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501162
Principal investigator 1 Incyte Corporation $9.27 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501165
Principal investigator 1 Incyte Corporation $2.12 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501169
Principal investigator 1 Incyte Corporation $51.50 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501173
Principal investigator 1 Incyte Corporation $5.15 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501177
Principal investigator 1 Incyte Corporation $24.68 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501181
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501186
Principal investigator 1 Incyte Corporation $8.22 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501190
Principal investigator 1 Incyte Corporation $34.35 04/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, LLC
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240501194
Principal investigator 1 SANOFI US SERVICES INC. $8,397.79 04/02/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116503
Principal investigator 1 Incyte Corporation $2,865.00 04/01/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500648
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,719.16 03/26/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223277037
Principal investigator 1 Eli Lilly and Company $1,163.11 03/25/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH INC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187880519
Principal investigator 1 Incyte Corporation $20,787.00 03/19/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240500506
Principal investigator 1 Eli Lilly and Company $11,625.84 03/18/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
AN OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN ADULT AND ADOLESCENT PARTICIPANTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS PREVIOUSLY TREATED WITH DUPILUMAB No dispute reported 06/30/2026 1187872307
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 03/14/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276715
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 03/14/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276717
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 03/14/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276719
Principal investigator 1 Eli Lilly and Company $2,228.50 03/10/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH INC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187874201
Principal investigator 1 ABBVIE INC. $12,337.50 03/07/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202461756
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,421.32 03/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276011
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $20.00 03/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276013
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 03/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223276015
Principal investigator 1 Incyte Corporation $297.70 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498440
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498445
Principal investigator 1 Incyte Corporation $10.60 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498449
Principal investigator 1 Incyte Corporation $32.36 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498462
Principal investigator 1 Incyte Corporation $123.40 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498471
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498475
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498480
Principal investigator 1 Incyte Corporation $41.10 03/03/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498485
Principal investigator 1 Incyte Corporation $1,798.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500514
Principal investigator 1 Incyte Corporation $1,798.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500566
Principal investigator 1 Incyte Corporation $1,798.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500600
Principal investigator 1 Incyte Corporation $1,798.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500604
Principal investigator 1 Incyte Corporation $2,610.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500620
Principal investigator 1 Incyte Corporation $2,610.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500624
Principal investigator 1 Incyte Corporation $1,798.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500627
Principal investigator 1 Incyte Corporation $1,798.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500632
Principal investigator 1 Janssen Research & Development, LLC $9,125.00 03/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421948
Principal investigator 1 ABBVIE INC. $4,632.92 02/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202454380
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $25,021.50 02/26/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223275611
Principal investigator 1 SANOFI US SERVICES INC. $8,839.59 02/24/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116495
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,303.48 02/21/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275445
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,063.72 02/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH NEDA
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190312905
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 02/14/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275317
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 02/14/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 02/14/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $200.00 02/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275169
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 02/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275171
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 02/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223275173
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 02/12/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223275175
Principal investigator 1 Janssen Research & Development, LLC $11,712.00 02/07/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1175421967
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,050.31 02/07/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223274979
Principal investigator 1 ABBVIE INC. $6,529.60 02/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1202447724
Principal investigator 1 ABBVIE INC. $6,527.60 02/06/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
M24-541 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body) No dispute reported 06/30/2026 1202447727
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $31,776.85 02/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274827
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 02/05/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274829
Principal investigator 1 SANOFI US SERVICES INC. $17,172.98 02/04/2025 Non-covered Recipient Entity
Allcutis Research Llc
Topical Corticosteroids Combo vs Placebo Study in Pts. with Moderate to Severe AD No dispute reported 06/30/2026 1226116436
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,537.91 02/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274625
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $300.00 02/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis No dispute reported 06/30/2026 1223274627
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $450.00 02/03/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274629
Principal investigator 1 Incyte Corporation $228.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500511
Principal investigator 1 Incyte Corporation $2,610.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500554
Principal investigator 1 Incyte Corporation $486.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500557
Principal investigator 1 Incyte Corporation $71.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500569
Principal investigator 1 Incyte Corporation $1,395.90 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500578
Principal investigator 1 Incyte Corporation $1,926.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500583
Principal investigator 1 Incyte Corporation $1,798.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500587
Principal investigator 1 Incyte Corporation $1,798.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500591
Principal investigator 1 Incyte Corporation $1,865.43 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500596
Principal investigator 1 Incyte Corporation $1,926.00 01/27/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500635
Principal investigator 1 Incyte Corporation $30.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500518
Principal investigator 1 Incyte Corporation $75.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500561
Principal investigator 1 Incyte Corporation $45.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500574
Principal investigator 1 Incyte Corporation $80.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500608
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $40.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $400.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274463
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $80.00 01/24/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 60 WEEKS OF TREATMENT WITH A WITHDRAWAL AND RETREATMENT PERIOD No dispute reported 06/30/2026 1223274465
Principal investigator 1 Incyte Corporation $2,393.00 01/17/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500539
Principal investigator 1 Incyte Corporation $2,393.00 01/17/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500612
Principal investigator 1 Incyte Corporation $2,393.00 01/17/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500616
Principal investigator 1 Incyte Corporation $9,879.00 01/17/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240501132
Principal investigator 1 Incyte Corporation $1,798.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500522
Principal investigator 1 Incyte Corporation $1,798.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500526
Principal investigator 1 Incyte Corporation $2,610.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500531
Principal investigator 1 Incyte Corporation $2,610.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500535
Principal investigator 1 Incyte Corporation $486.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500541
Principal investigator 1 Incyte Corporation $1,926.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500546
Principal investigator 1 Incyte Corporation $2,768.00 01/15/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240500550
Principal investigator 1 Eli Lilly and Company $1,468.00 01/13/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES AND RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BARICITINIB IN ADULT PATIENTS WITH SEVERE OR VERY SEVERE ALOPECIA AREATA No dispute reported 06/30/2026 1187873545
Principal investigator 1 Eli Lilly and Company $50,254.00 01/13/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSO) No dispute reported 06/30/2026 1187875907
Principal investigator 1 Eli Lilly and Company $193,009.00 01/08/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A PHASE 2B, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE ELTREKIBART IN ADULT PARTICIPANTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA No dispute reported 06/30/2026 1187875931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,737.66 01/08/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT No dispute reported 06/30/2026 1223273775
Principal investigator 1 Incyte Corporation $3,724.00 01/07/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH, INC PORTSMOUTH
A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participants With Nonsegmental Vitiligo No dispute reported 06/30/2026 1240501128
Principal investigator 1 ABBVIE INC. $574.77 01/02/2025 Non-covered Recipient Entity
ALLCUTIS RESEARCH LLC
M16-047 - A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis No dispute reported 06/30/2026 1202434272
Principal investigator 1 Incyte Corporation $1.24 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498382
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498385
Principal investigator 1 Incyte Corporation $45.80 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498389
Principal investigator 1 Incyte Corporation $98.72 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498394
Principal investigator 1 Incyte Corporation $160.30 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498398
Principal investigator 1 Incyte Corporation $148.08 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498403
Principal investigator 1 Incyte Corporation $249.08 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498407
Principal investigator 1 Incyte Corporation $64.72 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498411
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498415
Principal investigator 1 Incyte Corporation $249.08 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498419
Principal investigator 1 Incyte Corporation $177.39 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498423
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498427
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498431
Principal investigator 1 Incyte Corporation $29.16 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498436
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498453
Principal investigator 1 Incyte Corporation $49.32 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498458
Principal investigator 1 Incyte Corporation $12.72 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498467
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498489
Principal investigator 1 Incyte Corporation $32.88 01/02/2025 Non-covered Recipient Entity
ACTIVMED PRACTICES RESEARCH, LLC BEVERLY
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1240498493